Clinical Trial Update: A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. [Phase 1]

View source ↗

Summary

A Phase 1 trial of ARV-393 is evaluating safety and dosing for Relapsed/Refractory mature B-cell Non-Hodgkin lymphoma and Relapsed/Refractory angioimmunoblastic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioimmunoblastic T-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• ARV-393 (ARV-393)

Snippet

Sponsor: Arvinas Inc. | Conditions: Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL) | Phase 1 | Status: RECRUITING